Meeting Materials
Annual Report
View an enhanced version of our Annual Report.
Proxy Statement
View an enhanced version of our Proxy Statement.
View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Please be sure to vote your shares. Vote online or by phone by dialing 866-430-8263 .
June 1, 2022
9:30 AM ET
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, and exploring their potential to provide deep, durable, and potentially curative responses. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells, leaving the healthy immune system intact. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation (CABA™) platform, has applicability across more than two dozen B cell-mediated autoimmune diseases. Using our CABA™ platform, we have discovered and developed five disclosed product candidates, including our lead clinical-stage therapy in development to treat patients with mucosal pemphigus vulgaris. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop CAAR T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and engineered T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of CAAR T product candidates.